Dynamic contrast-enhanced MRI studies in oncology with an emphasis on quantification, validation and human studies

Clinical Radiology

Volumn 56, Issue 8, 2001, Pages 607-620

  Padhani, Anwar R ^a,b   Husband, Janet E ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Contrast enhancement; Magnetic resonance imaging (MRI); Perfusion; Vascular permeability

Indexed keywords

ANGIOGENESIS INHIBITOR; CONTRAST MEDIUM; GADOLINIUM;

ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL STUDY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORRELATION FUNCTION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KINETICS; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOLOGY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; TREATMENT OUTCOME; TUMOR; VALIDATION PROCESS;

EID: 0035428054     PISSN: 00099260     EISSN: None     Source Type: Journal    
DOI: 10.1053/crad.2001.0762     Document Type: Review

References (135)

1. Tumor angiogenesis: Tutorial on implications for imaging
2. Tumor angiogenesis: Molecular pathology, therapeutic targeting, and imaging
3. Angiogenesis imaging
4. MRI applications in the evaluation of tumor angiogenesis
5. In vivo monitoring of tumor angiogenesis with MR imaging
6. Autoregulation of angiogenesis by cells of the vessel wall
7. Angiogenesis and oxygen transport in solid tumors
8. What is the evidence that tumors are angiogenesis dependent?
9. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor on radiotherapy
10. Microenvironmental control of gene expression: Implications for tumor angiogenesis, progression, and metastasis
11. Theoretical simulation of oxygen transport to tumors by three-dimensional networks of microvessels
12. Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker
13. Physiology of the acute wound
14. Early wound healing exhibits cytokine surge without evidence of hypoxia
15. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
16. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: Role of vascular endothelial growth factor
17. Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells
18. Vascular endothelial growth factor (VEGF) and its receptors
19. Tumoural vascularity as a prognostic factor in cancer patients: The evidence continues to grow
20. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin
21. Tumor development under angiogenic signaling: A dynamical theory of tumor growth, treatment response, and postvascular dormancy
22. New perspectives in clinical oncology from angiogenesis research
23. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis
24. Angiogenesis and blood flow in solid tumors
25. Fourier analysis of fluctuations of oxygen tension and blood flow in R3230Ac tumors and muscle of rats
26. Consequences of angiogenesis for tumor progression, metastasis and cancer therapy
27. Immunophenotype of intraductal carcinoma
28. Ductal carcinoma in situ: MR imaging-histopathologic correlation
29. Expression of Tie2/Tek in breast tumour vasculature provides a new marker for evaluation of tumour angiogenesis
30. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy
31. Vascular endothelial growth factor (VEGF) in human breast cancer: Correlation with disease-free survival
32. Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma
33. Theory of use of indicators to measure blood flow and extraceliular volume and calculation of trans capillary movement of tracers
34. The permeability of capillaries in various organs as determined by the use of 'indicator diffusion' method
35. The theory and applications of the exchange of inert gas at the lungs and tissues
36. Role of radionuclide imaging in trials of antiangiogenic therapy
37. Application of CT in the investigation of angiogenesis in oncology
38. Evaluation of tumor angiogenesis with US: Imaging, Doppler, and contrast agents
39. Susceptibility contrast imaging of cerebral blood volume: Human experience
40. Cerebral blood flow: Assessment with dynamic contrast-enhanced T2*-weighted MR imaging at 1.5 T
41. Comparison of gradient- and spin-echo imaging: CBF, CBV, and MTT measurements by bolus tracking
42. NMR imaging of changes in vascular morphology due to tumor angiogenesis
43. Effects of three different doses of a bolus injection of gadodiamide: Assessment of regional cerebral blood volume maps in a blinded reader study
44. Contrast agents in functional MR imaging
45. Quantification of regional cerebral blood flow and volume with dynamic susceptibility contrast-enhanced MR imaging
46. Effect of radiation on blood volume in low-grade astrocytomas and normal brain tissue: Quantification with dynamic susceptibility contrast MR imaging
47. Optimization of fast acquisition methods for whole-brain relative cerebral blood volume (rCBV) mapping with susceptibility contrast agents
48. Differentiation between the effects of T1 and T2* shortening in contrast-enhanced MRI of the breast
49. Comparison of Gd- and Dy-chelates for T2 contrast-enhanced imaging
50. Recurrent brain tumour versus radiation necrosis: Comparison of MR relative cerebral blood volume maps and FDG-PET
51. Contrast-to-noise ratio in functional MRI of relative cerebral blood volume with sprodiamide injection
52. Characterization of hepatic lesions by perfusion-weighted MR imaging with an echoplanar sequence
53. Breast neoplasms: T2* susceptibility-contrast, first-pass perfusion MR imaging
54. Differentiating benign and malignant breast lesions with T2*-weighted first pass perfusion imaging
55. Invasive carcinomas and fibroadenomas of the breast: Comparison of microvessel distributions-implications for imaging modalities
56. Optimizing microvessel counts according to tumor zone in invasive ductal carcinoma of the breast
57. Breast lesions: Correlation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis
58. Cerebral blood volume maps of gliomas: Comparison with tumor grade and histologic findings
59. Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas
60. Echo-planar MR cerebral blood volume mapping of gliomas. Clinical utility
61. Glial neoplasms: Dynamic contrast-enhanced T2*-weighted MR imaging
62. Gliomas: Correlation of magnetic susceptibility artifact with histologic grade
63. Breast masses with peripheral rim enhancement on dynamic contrast-enhanced MR images: Correlation of MR findings with histologic features and expression of growth factors
64. Angiogenesis and dynamic MR imaging gadolinium enhancement of malignant and benign breast lesions
65. Angiogenesis of uterine cervical carcinoma: Characterization by pharmacokinetic magnetic resonance parameters and histological microvessel density with correlation to lymphatic involvement
66. MRI enhancement and microvascular density in gliomas. Correlation with tumor cell proliferation
67. Microvessel density of invasive breast cancer assessed by dynamic Gd-DTPA enhanced MRI
68. Dynamic echo-planar imaging of the breast: Experience in diagnosing breast carcinoma and correlation with tumor angiogenesis
69. Tumour oxygenation levels correlate with dynamic contrast-enhanced magnetic resonance imaging parameters in carcinoma of the cervix
70. Pathophysiologic basis of contrast enhancement in breast tumors
71. Dynamic contrast-enhanced magnetic resonance imaging reveals stress-induced angiogenesis in MCF7 human breast tumors
72. Comparison of vascular volume and permeability for tumours derived from metastatic human breast cancer cell with and without metastasis supressor gene nm23
73. Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor
74. Dynamic contrast enhanced MR imaging in the evaluation of antiangiogenesis therapy
75. Dynamic contrast-enhanced MR imaging of uterine cervical cancer: Pharmacokinetic analysis with histopathologic correlation and its importance in predicting the outcome of radiation therapy
76. Physiologic measurements by contrast-enhanced MR imaging: Expectations and limitations
77. Key factors in the acquisition of contrast kinetic data for oncology
78. Probing tumor microvascularity by measurement, analysis and display of contrast agent uptake kinetics
79. Differentiation of benign from malignant breast masses by time-intensity evaluation of contrast enhanced MRI
80. MR imaging of the breast: Fast imaging sequences with and without Gd-DTPA. Preliminary observations
81. Comparative signal intensity measurements in dynamic gadolinium-enhanced MR mammography
82. Dynamic breast MR imaging: Are signal intensity time course data useful for differential diagnosis of enhancing lesions?
83. Pharmacokinetic mapping of the breast: A new method for dynamic MR mammography
84. Improving image quality and T(1) measurements using saturation recovery turbo-FLASH with approximate K-space normalisation filter
85. Modeling tracer kinetics in dynamic Gd-DTPA MR imaging
86. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: Standardized quantities and symbols
87. Quantitative analysis of dynamic Gd-DTPA enhancement in breast tumors using a permeability model
88. Pharmacokinetic analysis of Gd-DTPA enhancement in dynamic three-dimensional MRI of breast lesions
89. Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: Preliminary results
90. Magnetic resonance imaging screening in women at genetic risk of breast cancer: Imaging and analysis protocol for the UK multicentre study
91. First experiences in screening women at high risk for breast cancer with MR imaging
92. Benign and malignant musculoskeletal lesions: Dynamic contrast-enhanced MR imaging-parametric 'first-pass' images depict tissue vascularization and perfusion
93. MR characterization of suspicious breast lesions with a gadolinium-enhanced Turbo-FLASH subtraction technique
94. Assessment of breast cancer recurrence with contrast-enhanced subtraction MR imaging: Preliminary results in 26 patients
95. MR imaging of the breast with Gd-DTPA: Use and limitations
96. Suspect breast lesions: Findings at dynamic gadolinium-enhanced MR imaging correlated with mammographic and pathologic features
97. Breast MR imaging with commercially available techniques: Radiologic-pathologic correlation
98. The variability of fibroadenoma in contrast-enhanced dynamic MR mammography
99. Dynamic contrast enhanced MRI of prostate cancer: Correlation with morphology and tumour stage, histological grade and PSA
100. Fast dynamic gadolinium-enhanced MR imaging of urinary bladder and prostate cancer
101. MRI of the uterus, uterine cervix, and vagina: Diagnostic performance of dynamic contrast-enhanced fast multiplanar gradient-echo imaging in comparison with fast spin-echo T2-weighted pulse imaging
102. Staging urinary bladder cancer after transurethral biopsy: Value of fast dynamic contrast-enhanced MR imaging
103. Dynamic TurboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: Correlation with histopathologic results
104. Contrast-enhanced endorectal coil MRI in local staging of prostate carcinoma
105. Evaluation of chemotherapy in advanced urinary bladder cancer with fast dynamic contrast-enhanced MR imaging
106. Dynamic MR imaging (DEMRI) of microcirculation in bone sarcoma
107. Osteosarcoma and Ewing's sarcoma after neoadjuvant chemotherapy: Value of dynamic MR imaging in detecting viable tumor before surgery
108. MR mammography with pharmacokinetic mapping for monitoring of breast cancer treatment during neoadjuvant therapy
109. Response of Breast carcinoma to Chemotherapy - MR Permeability changes using Histogram Analysis
110. Monitoring of tumor microcirculation during fractionated radiation therapy in patients with rectal carcinoma: Preliminary results and implications for therapy
111. Pixel analysis of MR perfusion imaging in predicting radiation therapy outcome in cervical cancer
112. Effects of androgen deprivation treatment on prostate morphology and vascular permeability evaluated by magnetic resonance imaging
113. Uterine fibroleiomyoma: MR imaging appearances before and after embolization of uterine arteries
114. Symptomatic fibroleiomyomata: MR imaging of the uterus before and after uterine arterial embolization
115. Semiquantitative assessment of uterine perfusion using first pass dynamic contrast-enhanced MR imaging for patients treated with uterine fibroid embolization
116. Angiogenic activity of cervical carcinoma: Assessment by functional magnetic resonance imaging-based parameters and a histomorphological approach in correlation with disease outcome
117. Tumor perfusion studies using fast magnetic resonance imaging technique in advanced cervical cancer: A new noninvasive predictive assay
118. Tumor recurrence versus fibrosis in the irradiated breast: Differentiation with dynamic gadolinium-enhanced MR imaging
119. Contrast-enhanced MRI of the breast after limited surgery and radiation therapy
120. Dynamic contrast-enhanced and fat suppressed magnetic resonance imaging in suspected recurrent carcinoma of the breast: Preliminary experience
121. Dynamic contrast-enhanced magnetic resonance imaging of the breast combined with pharmacokinetic analysis of gadolinium-DTPA uptake in the diagnosis of local recurrence of early stage breast carcinoma
122. Dynamic contrast-enhanced subtraction versus T2-weighted spin-echo MR imaging in the follow-up of colorectal neoplasm: A prospective study of 41 patients
123. Quantitative dynamic contrast enhanced MRI of recurrent pelvic masses in patients treated for cancer
124. The pelvis after surgery and radio-chemotherapy for rectal cancer studied with Gd-DTPA-enhanced fast dynamic MR imaging
125. Mapping pathophysiological features of breast tumors by MRI at high spatial resolution
126. Contrast-enhanced MR imaging of the breast: Comparison of two different doses of gadopentetate dimeglumine
127. Multicompartment analysis of gadolinium chelate kinetics: Blood-tissue exchange in mammary tumors as monitored by dynamic MR imaging
128. Dynamic contrast-enhanced MRI in the differentiation of breast tumors: User-defined versus semi-automated region-of-interest analysis
129. MRIW: Parametric analysis software for contrast-enhanced dynamic MR imaging in cancer
130. Assessing tumor response to treatment: Histogram analysis of parametric maps of tumor vascular function derived from dynamic contrast enhanced MR images 2000
131. Quantification of endothelial permeability, leakage space, and blood volume in brain tumors using combined T1 and T2* contrast-enhanced dynamic MR imaging
132. Breast carcinoma: Effect of preoperative contrast-enhanced MR imaging on the therapeutic approach
133. Staging of symptomatic primary breast cancer with MR imaging
134. Role of imaging in clinical trials of antiangiogenesis therapy in oncology
135. Gd-enhanced dynamic magnetic resonance imaging of breast masses